Houston Exponential has announced the 38 finalists for the inaugural Listies Awards. Photo via Getty Images

Ever wonder what Houston startups and innovators are the best of the best? Here's your chance to figure it out. The inaugural Listies awards program has named its finalists.

The Listies, brought to you by Houston Exponential in partnership with InnovationMap, will name the winning companies and people across 12 awards on November 20 at 3 pm at a virtual event as a part of Impact Hub's annual The Houston Innovation Summit (THIS). Click here to register for the free event.

Nominations were open until Friday, November 6, and then a group of judges made up of members of the Houston innovation ecosystem reviewed the submissions to settle on the finalists. Below, in alphabetical order, the 38 finalists are listed for each category.

DEI champion

  • Heath Butler
  • Maria Maso
  • Grace Rodriguez

Individual contributor

  • Michael Matthews
  • Slawek Omylski
  • Brad True

Mentor of the year

  • Keith Kreuer
  • Wade Pinder
  • Landi Spearman

Outstanding leadership

  • Stephanie Campbell
  • Grace Rodriguez
  • Roberta Schwartz

Corporate innovation

  • Chevron Technology Ventures
  • Houston Methodist
  • Shell Ventures

Investor of the year

  • CSL Capital Management
  • Golden Section VC (GSTVC)
  • Integr8d Capital

SDO superstar

  • MassChallenge Houston
  • Rice Alliance
  • TMCx

Welcome to Houston

  • Greentown Labs
  • TestCard
  • Win-Win

Civic engagement

  • Annapurna
  • Luminare
  • McMac Cx

COVID pivot/phoenix

  • Luminare
  • re:3D
  • sEATz

People choice

  • INK
  • Liongard
  • Luminare
  • re:3D
  • Topl

Soonicorn

  • GoExpedi
  • Liongard
  • Medical Informatics Corp.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”